Despite various global lockdowns during the ongoing COVID-19 pandemic, the development of gene therapy products is on a significant upward curve with record fundraising in 2020. However, manufacturing is an increasing bottleneck in realizing the full potential of many DNA and viral vector facilities, and COVID vaccine production will have undoubtedly exposed this shortfall in production capacity. Such a deficit was and is being addressed on one level by significant investment in production facilities, and secondly by the development of…